A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - wkzo.com
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - MSN
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza Sales Grow on New Contract Momentum - The Wall Street Journal
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review
Lonza forecasts 2026 sales growth of 11-12% for core CDMO business - Global Banking & Finance Review
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration - TradingView
Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration - TradingView
Lonza Group AG (LONN.SW, SIX): CHF550.20 intraday ahead of 28 Jan earnings — what to watch - Meyka
Lonza Group AG (LONN.SW, SIX): CHF550.20 intraday ahead of 28 Jan earnings — what to watch - Meyka
CHF555.20 Lonza Group AG (LONN.SW, SIX) intraday before Jan 28 earnings: key metrics to watch - Meyka
CHF555.20 Lonza Group AG (LONN.SW, SIX) intraday before Jan 28 earnings: key metrics to watch - Meyka
Cell Therapy Bioprocessing Market Is Going to Boom |• Lonza • Thermo Fisher Scientific - openPR.com
Cell Therapy Bioprocessing Market Is Going to Boom |• Lonza • Thermo Fisher Scientific - openPR.com
Lonza Group (OTCMKTS:LZAGY) Sees Large Volume Increase - Time to Buy? - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Large Volume Increase - Time to Buy? - MarketBeat
Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? - DCAT Value Chain Insights
Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? - DCAT Value Chain Insights
Lonza Group (OTCMKTS:LZAGY) Trading Down 1.8% - What's Next? - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Trading Down 1.8% - What's Next? - MarketBeat
A Smarter, Faster Way to Perform Gel Electrophoresis - the-scientist.com
A Smarter, Faster Way to Perform Gel Electrophoresis - the-scientist.com
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page